The National Medical Products Administration Approves the Marketing of 盐酸匹米替尼胶囊

2025.12.23 Recently, the National Medical Products Administration (NMPA) has approved the marketing of 盐酸匹米替尼胶囊(商品名：贝捷迈), a Class 1 innovative drug filed by Merck Serono (Beijing) Pharmaceutical Co., Ltd., via the priority review and approval process. This drug is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may lead to functional limitations or severe complications. The launch of this medication provides a new treatment option for relevant patients.